A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson’s disease

por Tanabe, Akie, Yamamura, Yukio, Kasahara, Jiro, Morigaki, Ryoma, Kaji, Ryuji, Goto, Satoshi
Publicado 2014

c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism

por Zhou, Yu, Yamamura, Yukio, Ogawa, Masatoshi, Tsuji, Ryosuke, Tsuchiya, Koichiro, Kasahara, Jiro, Goto, Satoshi
Publicado 2018

Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson’s disease

por Kadoguchi, Naoto, Okabe, Shinji, Yamamura, Yukio, Shono, Misaki, Fukano, Tatsuya, Tanabe, Akie, Yokoyama, Hironori, Kasahara, Jiro
Publicado 2014

Quantitative activation-induced manganese-enhanced MRI reveals severity of Parkinson’s disease in mice

por Kikuta, Satomi, Nakamura, Yukiyo, Yamamura, Yukio, Tamura, Atsushi, Homma, Noriyasu, Yanagawa, Yuchio, Tamura, Hajime, Kasahara, Jiro, Osanai, Makoto
Publicado 2015

Dopamine signaling negatively regulates striatal phosphorylation of Cdk5 at tyrosine 15 in mice

por Yamamura, Yukio, Morigaki, Ryoma, Kasahara, Jiro, Yokoyama, Hironori, Tanabe, Akie, Okita, Shinya, Koizumi, Hidetaka, Nagahiro, Shinji, Kaji, Ryuji, Goto, Satoshi
Publicado 2013